Our physician scientists work with a talented group of researchers to investigate the causes of immune system disorders. We collaborate with pharmaceutical companies in the Boston area to develop new treatments for lupus and other autoimmune diseases.
Our patients are vital partners in this research. We are currently enrolling patients with all forms of lupus, patients with autoimmune diseases other than lupus, and patients with chronic kidney disease in an Autoimmune Disease Registry and Repository. The goal of the registry and repository is to use patient samples collected for research purposes to advance our understanding of how the immune system attacks healthy cells and causes organ injury and to identify new targets for therapy.
We are also enrolling patients in research studies that involve a single blood donation to compare immune cell function between diseased individuals and healthy volunteers and to investigate how variations in genes (inherited from your parents) may contribute to the development of lupus.
If you are interested in participating in one of our research studies, please contact Britte Beaudette-Zlatanova, Ph.D. at 617.638.5965.
To learn more about lupus research at Boston Medical Center, please visit our team members’ profiles.
Many of lupus patients, despite receiving the standard-of-care treatment for lupus or lupus nephritis, still do not achieve a complete remission. Some patients cannot tolerate the standard-of-care treatments because they develop significant side effects.
We offer patients the opportunity to participate in clinical trials and receive investigational treatments for lupus. Investigational treatments are medications that are not currently approved by the Food and Drug Administration to treat lupus. To learn more about what a clinical trial is, visit clinicaltrials.gov and select “About Clinical Studies.”
We are currently enrolling patients in the following clinical trials:
I. Sponsor: AstraZeneca
Study Drug: Anifrolumab
Patient population: Systemic lupus erythematosus (SLE)
Title of study: A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study evaluating the efficacy and safety of Anifrolumab in adult subjects with active systemic lupus erythematosus
For more information about the outcome measures of the study and eligibility criteria, visit clinicaltrials.gov and type in the identifier NCT02446912
II. Sponsor: AstraZeneca
Study Drug: Anifrolumab
Patient population: Lupus Nephritis
Title of study: A multicenter, randomized, double-blind, placebo-controlled, Phase 2 study evaluating the efficacy and safety of Anifrolumab in adult subjects with active proliferative lupus nephritis
For more information about the outcome measures of the study and eligibility criteria, visit clinicaltrials.gov and type in the identifier NCT02547922
To learn more about clinical trials at Boston Medical Center or to refer a patient for a clinical trial, please contact the Clinical Trial Manager, Britte Beaudette-Zlatanova, Ph.D. at 617.638.5965.